Hematological Markers Predict Immune‐Related Adverse Events in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Pembrolizumab
Asia-Pacific Journal of Clinical Oncology · 2025
DOI: 10.1111/ajco.70012 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Asia-Pacific Journal of Clinical Oncology, 2025. Verfasst von Takashi Matsuki und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Head and Neck Surgery, Kanagawa Cancer Center, Yokohama, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Head and Neck Neoplasms, Neoplasm Recurrence, Local, Squamous Cell Carcinoma of Head and Neck. Die Arbeit nennt 25 Literaturangaben.
Themen: Patientensicherheit
Abstract (Originalsprache)
Background
In patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN), the correlation between hematological markers and treatment outcomes has been established. However, their predictive role in the development of immune‐related adverse events (irAEs) remains unclear.
Methods
We conducted a multicenter retrospective cohort study to evaluate whether pre‐treatment hematological markers—including neutrophil‐to‐lymphocyte ratio (NLR), platelet‐to‐lymphocyte ratio (PLR), lymphocyte‐to‐monocyte ratio (LMR), and the CRP‐albumin‐lymphocyte (CALLY) index—predict the development of irAEs in 147 patients with R/M SCCHN treated with pembrolizumab.
Results
Lower NLR and PLR, as well as higher LMR and CALLY index, were significantly associated with a higher incidence of irAEs. Furthermore, NLR and LMR were significantly correlated with the occurrence of severe (Grade ≥ 3) irAEs.
Conclusion
Pre‐treatment NLR, PLR, LMR, and CALLY index may serve as useful predictive markers for the development of irAEs in patients with R/M SCCHN treated with pembrolizumab.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Head and Neck Surgery, Kanagawa Cancer Center, Yokohama, Japan.
- Department of Otorhinolaryngology, Head and Neck Surgery, Kitasato University School of Medicine, Sagamihara, Japan.
- Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University School of Medicine, Tokyo, Japan.
- Department of Head and Neck Oncology, National Cancer Center Hospital, Tokyo, Japan.
- Department of Otorhinolaryngology, Head and Neck Surgery, Yokohama City University, School of Medicine, Yokohama, Japan.
- Department of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, Tokyo, Japan.
Zitieren
APA
Matsuki, T., Okada, T., Fushimi, C., Takahashi, H., Okamoto, I., Kondo, T., Tokashiki, K., Hanyu, K., Kishida, T., Ito, T., Yamashita, G., Tsukahara, K., Masubuchi, T., Tada, Y., Momiyama, K., Asako, Y., Hagiwara, K., Ikemiyagi, H., Yaguchi, R., …, & Yamashita, T. (2025). Hematological Markers Predict Immune‐Related Adverse Events in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Pembrolizumab. Asia-Pacific Journal of Clinical Oncology. https://doi.org/10.1111/ajco.70012
Vancouver
Matsuki T, Okada T, Fushimi C, Takahashi H, Okamoto I, Kondo T, et al. Hematological Markers Predict Immune‐Related Adverse Events in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Pembrolizumab. Asia-Pacific Journal of Clinical Oncology. 2025. doi:10.1111/ajco.70012
BibTeX
@article{Matsuki2025,
author = {Matsuki, Takashi and Okada, Takuro and Fushimi, Chihiro and Takahashi, Hideaki and Okamoto, Isaku and Kondo, Takahito and Tokashiki, Kunihiko and Hanyu, Kenji and Kishida, Takuma and Ito, Tatsuya and Yamashita, Gai and Tsukahara, Kiyoaki and Masubuchi, Tatsuo and Tada, Yuichiro and Momiyama, Kaho and Asako, Yukiko and Hagiwara, Kohei and Ikemiyagi, Hidetaka and Yaguchi, Ryohei and Oridate, Nobuhiko and Omura, Go and Yamashita, Taku},
title = {Hematological Markers Predict Immune‐Related Adverse Events in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Pembrolizumab},
journal = {Asia-Pacific Journal of Clinical Oncology},
year = {2025},
doi = {10.1111/ajco.70012}
}
EUVIMED